Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Immunotherapy improves prognosis for women with recurrent ovarian cancer in clinical trial

Results from a clinical trial show that a new immunotherapy treatment, when added to standard chemotherapy, significantly prolongs survival in women with recurrent ovarian cancer.

The randomised phase II trial compared overall survival of women who received chemotherapy with and without immunotherapy for recurrent ovarian cancer.

Women treated with a combination of chemotherapy and immunotherapy experienced significantly prolonged survival.

The treatment is referred to as dendritic cell-based immunotherapy.

It uses the patient’s own immune system to combat cancer and offers long-lasting antitumor immunity.

Immunotherapies are one of the newest and most promising treatments for ovarian cancer, which typically is diagnosed at a later stage and subsequently harder to treat.

David Cibula, MD, PhD, a physician with Gynecologic Oncology Centre, First Faculty of Medicine, Charles University and General University Hospital in Prague, presented the results at the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer.

"The most important objective of cancer treatment is to prolong overall survival while maintaining a good quality of life during treatment. A major advantage of this immunotherapy is an excellent safety profile and tolerance by patients thanks to an almost absence of any toxicity,” said Dr Cibula

“There are currently not many other alternatives in clinical development with such promising results,” added Dr Cibula

A larger phase III clinical trial is planned for 2019.

Source: The Society of Gynecologic Oncology

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation